|
|
Influence of Traditional Chinese medicine combined with transcatheter arterial chemoembolization on immune function of primary liver cancer patients |
MIAO Tongguo, MA Liwei, WANG Lijing, CHEN Wusheng, SHAO Mingliang, and DUAN Yusong |
Department of Interventional Radiology, Fifth Hospital of Shijiazhuang, Shijiazhuang 050021, China |
|
|
Abstract Objective To explore the influence of Traditional Chinese Medicine combined with transcatheter arterial chemoembolization (TACE) on immune function in primary liver cancer patients. Methods A total of 80 patients with pathologically-proved PLC were enrolled in this study, and randomly divided into a study group and a control group.The study group was treated with TCM combined TACE, while the control group was treated by TACE alone. Peripheral blood T lymphocyte subsets cells, AFP, CD4+CD25+ Treg cell, as well as the therapeutic effect, Karnofsky sore (KPS) were determined 24 h before treatment and one, and 4 weeks after treatment. The Results were statistically analyzed.Results At the end of the first week after treatment, the preoperative peripheral T lymphocyte subsets CD3+(45.26±2.83) vs (50.16±6.31), CD4+(22.65±2.35) vs (27.12±3.36) T cells and CD4+/CD8+(0.85±0.16) vs (1.16±0.27) in the study group were significantly lower,while CD8+(32.48±6.21) vs (27.36±5.64) T cells, CD4+CD25+(12.65±5.12) vs (9.15±3.63) Treg cells were significantly higher than that before treatment(P<0.05). However, in control group, the peripheral T lymphocyte subsets CD3+, CD4+, CD8+T cells and CD4+/CD8+ were not statistically significantly different. After 4 weeks,for two groups, the peripheral T lymphocyte subsets CD3+(46.55±3.94) vs (49.33±3.12), CD4+(23.13±2.72) vs (25.53±2.52), CD8+(25.26±3.52) vs (27.69±5.13) T cells and CD4+/CD8+(1.13±0.39) vs (1.22±0.16) were significantly different (P<0.05). Treg cells, AFP, KPS were statistically significantly different when compared with those in the control group (P<0.05). Conclusions TCM combined with TACE can enhance the immunity and quality of life in patients with primary liver cancer.
|
Received: 09 March 2016
|
|
|
|
|
[1] |
中华人民共和国卫生部.原发性肝癌诊疗规范(2011版)[J].临床肝胆病杂志,2011,27(11):1141-1159.
|
[2] |
Song P, Tang W, Tamuras S,et al. The management of hepatocellular carcinoma in Asia:a guideline combining quantitative and qualitative evaluation[J].Biosci Trends,2010,4(6):283-287.
|
[3] |
Lencioni R. Loco-regional treatment of hepatocellular carcinoma[J].Hepatology,2010,52(2):762-773.
|
[4] |
O’Beirne J P, Harrison P M. The role of the immune system in the control of hepatocellular carcinoma[J].Eur J Gastroenterol Hepatol,2004,16:1257-1260.
|
[5] |
王志利,张跃伟,徐丹凤.射频消融治疗肝癌后机体免疫功能变化的研究进展[J].当代医学,2012,18(14):24 -25.
|
[6] |
王立静,苗同国,宁更献,等.肝动脉化疗栓塞术对原发性肝癌患者T 淋巴细胞亚群的影响[J].介入放射学杂志,2015,24(2):174 -177.
|
|
|
|